Navigation Links
Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
Date:10/29/2009

by the use of forward-looking terminology such as "expect," "plans," "anticipates," "will," "expects," "goal" or similar expressions, or by express or implied statements with respect to the company's clinical development programs or commercialization activities in hepatitis C, or any potential pipeline candidates, including any expressed or implied statements regarding the efficacy and safety of IDX184, or any other product candidate and any future clinical trials involving our product candidates and expectations with respect to additional milestone payments, future royalty payments, funding of operations and future cash balances. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 3
'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
4. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
5. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
6. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
7. Idenix Pharmaceuticals Reports First Quarter Financial Results
8. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
9. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
10. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
11. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015 The National Necrotizing Fasciitis ... life—were saved by doctors at Vanderbilt University Hospital in ... NovaBay Pharmaceuticals and Dr. John Crew , director ... Seton Medical Center in Daly City, CA. ... breakthrough approach, pioneered by Dr. Crew, that had previously ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and six-month periods ended June 30, 2015. Biorem,s complete second quarter ... ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended ... 2014 , 2015 , 2014 Revenue ... , 4,433 Gross profit , 1,656 , ...
(Date:8/27/2015)... August 27, 2015 GlassesOff (OTCBB: GLSO), ... functions in the human vision system, announced today a partnership ... guard Chris Paul to develop a new mobile ... to improve their real-life on-court performance. Vision is ... it is shooting a ball or blocking a pass. The ...
(Date:8/27/2015)... ... 2015 , ... METTLER TOLEDO's web-based EasyFinder™ tool ... to a manageable shortlist of bench and floor scales and terminals. Specifying a ... with the customer’s industry and application. , Side-by-side product comparisons and an ...
Breaking Biology Technology:Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3METTLER TOLEDO Updates Online Scale Selection Tool 2
... Cephalon, Inc. (Nasdaq: CEPH ) today announced ... NUVIGIL® (armodafinil) Tablets [C-IV] in patients experiencing excessive sleepiness ... of their night shifts (i.e., 4:00 a.m. to 8:00 ... statistically significant difference in improvement in overall clinical condition ...
... Inc., a network of premier clinical research sites and ... research consultant and education provider, has earned status as ... presented by the Women,s Business Enterprise National Council (WBENC) ... The nationally recognized certification from WBENC helps to ...
... Jan. 25, 2011 Reportlinker.com announces ... is available in its catalogue: ... Chemistry and Immunodiagnostics Markets: US, Europe, ... Expansion Strategies for Instrumentand Reagent Suppliers ...
Cached Biology Technology:Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder 2Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder 3Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder 4RxTrials Earns National Women-Owned Business Certification 2Reportlinker Adds The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan Product Development Opportunities and Business Expansion Strategies for Instrumentand Reagent Suppliers 2
(Date:8/31/2015)... 31, 2015 Growing need for ... government digitization projects to drive India ... TechSci Research report, " India Biometrics Market Forecast & Opportunities, ... is projected to grow at a CAGR of over 35% ... on account of extensive use of biometric technology in the ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ) has announced the ... - Growth, Trends & Forecasts (2014-2020)" report to ... Sensors market is estimated at $0.23 billion by 2018 ... The near future will bring biomedical sensors ... individual. These sensors can be set to trigger alerts ...
(Date:8/28/2015)... August 28, 2015 According to ... Market by Assessment Type (Pen & Paper Based, Hosted, ... Corporate Learning, Academic Research), Vertical and Region - Global ... Training Market to grow from USD 2.4 Billion in ... Compound Annual Growth Rate (CAGR) of 25.6% from 2015 ...
Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4
... almost every plant species on the Iberian Peninsula had ... and Taraxacum lacianense , two dandelions from ... This finding confirms Spain,s privileged position as a hotbed ... now in Spain. It depends on the complexity of ...
... - William T. Talman, MD, President of the Federation ... Barack Obama for his continuing support for science and ... on research," Talman stated. In a letter to ... critical investmenteven during a time of unprecedented budgetary constraintswill ...
... More than a third of coral reef fish species ... climate change on coral reefs, a new scientific study has ... from individual locations, while they continue to persist elsewhere across ... international team of marine scientists has found that a third ...
Cached Biology News:2 new plants discovered in Spain 2Extinction predictor 'will help protect coral reefs' 2Extinction predictor 'will help protect coral reefs' 3
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Evolutionarily conserved signaling intermediate in Toll pathway...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Biology Products: